| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8833607 | Journal of the American College of Surgeons | 2018 | 8 Pages |
Abstract
Use of MSPs among patients with breast cancer has increased over time and is associated with a decreased use of adjuvant chemotherapy. Oncotype DX continues to be the most widely used MSP, although MP use has increased over time. Future studies are warranted to determine the optimal use of these MSPs in risk assessment and postoperative decision making.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Neal MD, Michael E. MD, MPH, Nicolás MD, FACS, Charles R. MD, MBA, FACS, Robert CG. MD, PhD, FACS, Kelly M. MD, PhD, FACS,